BOTHELL, Wash., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

Leen Kawas resigned as Athira's CEO in October 2021 after an investigation into her doctoral work. She's now forging a new path with a life sciences investment firm and telling her side of the story.

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options New York, New York ...

Athira Pharma’s experimental Alzheimer’s disease drug has failed a Phase 2 clinical trial and the working theory as to why is that the small molecule does not play well with widely prescribed ...

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going. Just a couple of weeks after announcing that ...

Athira Pharma CEO Leen Kawas accepts the award for CEO of the Year at the 2019 GeekWire Awards. (GeekWire Photo / Kevin Lisota) More than 5 million Americans have Alzheimer’s disease, and the ...

A panel of faculty members will decide on the number of papers I will have to clear.” said a beaming Athira. She joined the course in the 2014 batch when CET was under Kerala University.

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

The move follows months of inquiry during which the former Athira CEO was placed on temporary leave. Athira grant used doctor's credentials without his knowledge Questions around Athira echo ...

The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future. Looking for more investing ideas like this one? Get them ...

Athira Pharma’s stock has sold off some months ago on its Alzheimer’s drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show ...